Psybio Therapeutics Corp Stock Performance
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of 95.0, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PsyBio Therapeutics will likely underperform. Use PsyBio Therapeutics standard deviation, as well as the relationship between the maximum drawdown and day median price , to analyze future returns on PsyBio Therapeutics.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in PsyBio Therapeutics Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly conflicting fundamental drivers, PsyBio Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 269.7 K | |
| Total Cashflows From Investing Activities | -3.6 M | |
| Free Cash Flow | -6.9 M |
PsyBio |
PsyBio Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in PsyBio Therapeutics Corp on September 2, 2024 and sell it today you would earn a total of 0.00 from holding PsyBio Therapeutics Corp or generate 0.0% return on investment over 90 days. PsyBio Therapeutics Corp is currently producing 12.7048% returns and takes up 125.307% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than PsyBio, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PsyBio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PsyBio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PsyBio Therapeutics Corp, and traders can use it to determine the average amount a PsyBio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1014
| Best Portfolio | Best Equity | PSYBF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 125.31 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average PsyBio Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PsyBio Therapeutics by adding it to a well-diversified portfolio.
PsyBio Therapeutics Fundamentals Growth
PsyBio Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PsyBio Therapeutics, and PsyBio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PsyBio Pink Sheet performance.
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 3.69 M | |||
| Shares Outstanding | 80.85 M | |||
| Price To Book | 202.42 X | |||
| EBITDA | (10.91 M) | |||
| Cash And Equivalents | 911.83 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 207.81 K | |||
| Debt To Equity | 7.03 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.95 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 4.01 M | |||
About PsyBio Therapeutics Performance
By analyzing PsyBio Therapeutics' fundamental ratios, stakeholders can gain valuable insights into PsyBio Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PsyBio Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PsyBio Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. Psybio Therapeautics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about PsyBio Therapeutics Corp performance evaluation
Checking the ongoing alerts about PsyBio Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PsyBio Therapeutics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 |
- Analyzing PsyBio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PsyBio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PsyBio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PsyBio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PsyBio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PsyBio Therapeutics' pink sheet. These opinions can provide insight into PsyBio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PsyBio Pink Sheet analysis
When running PsyBio Therapeutics' price analysis, check to measure PsyBio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PsyBio Therapeutics is operating at the current time. Most of PsyBio Therapeutics' value examination focuses on studying past and present price action to predict the probability of PsyBio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PsyBio Therapeutics' price. Additionally, you may evaluate how the addition of PsyBio Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |